Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Respiratory Generics: Big Potential But A Tough Market To Crack

Executive Summary

With GlaxoSmithKline's blockbuster asthma drug Advair facing patent expiration later this year, generic drug makers like Teva and Sandoz are looking to pounce on the opportunity

Related Content

Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off
Prosonix Extends Series B Financing, Plans Generic Fluticasone Filing
Managing The World’s First Blockbuster Generic: An Interview With Sandoz’s George
With Federal Dollars Scarce, FDA May Fundraise For Regulatory Science Initiative
COPD Market Snapshot: Firms Brush Off Near-term Generic Challenges, Focus On Pipelines
LABA Label Changes Could Reinvigorate Single-Ingredient Products
Novartis' Sandoz Unit Makes Respiratory Push With Acquisition Of Oriel
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
“Difficult” Bioequivalence Issues Make Limited Progress At Advisory Cmte.
“Difficult” Bioequivalence Issues Make Limited Progress At Advisory Cmte.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts